Amneal Pharmaceuticals, Inc.

Filing receipts

“AvKARE The following table sets forth results of operations for our AvKARE segment for the three months ended March 31, 2026 and 2025 (in thousands): Three Months Ended March 31, Change 2026 2025 $ % Net revenue $ 166,017 $ 172,415 $ (6,398) (3.7) % Cost of goods sold 126,942 143,813 (16,871) (11.7) % Gross profit 39,075 28,602 10,473 36.6 % Selling, general and administrative 16,680 15,694 986 6.3 % Operating income $ 22,395 $ 12,908 $ 9,487 73.5 % 36 Net Revenue AvKARE net revenue for the three months ended March 31, 2026 decreased 3.7% as compared to the prior year period primarily driven by a reduction in our low margin distribution sales, partially offset by expansion in our government...”

“Decline in our AvKARE segment net revenue of $6.4 million , primarily driven by a reduction in our low margin distribution sales, partially offset by expansion in our government label channel from new product introductions.”

“Cost of Goods Sold and Gross Profit AvKARE cost of goods sold for the three months ended March 31, 2026 decreased 11.7% as compared to the prior year period primarily due to a reduction in inventory obsolescence of $6.5 million and reduced sales in our low margin distribution channel, partially offset by higher sales in our government label channel.”